Market research
MVR.F Medivir AB (publ)
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 36M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.35
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- SE0000273294
- Market cap
- 36M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.35
About
About Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MVR.F discussion.
5 years, 5 months ago
Medivir AB (publ) is currently in a long term downtrend where the price is trading 11.3% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.2.
Medivir AB (publ)'s total revenue sank by 22.8% to $1M since the same quarter in the previous year.
Its net income has increased by 114.4% to $5M since the same quarter in the previous year.
Finally, its free cash flow grew by 80.7% to $-5M since the same quarter in the previous year.
Based on the above factors, Medivir AB (publ) gets an overall score of 3/5.